Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial

被引:53
|
作者
Genovese, M. C. [1 ]
Bojin, S. [2 ]
Biagini, I. M. [3 ]
Mociran, E. [4 ]
Cristei, D. [5 ]
Mirea, G. [6 ]
Georgescu, L. [7 ]
Sloan-Lancaster, J. [8 ]
机构
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cty Hosp, Covasna, Romania
[3] Cty Hosp, Bacau, Romania
[4] Cty Hosp, Baia Mare, Romania
[5] Ctr Rheumatol, Braila, Romania
[6] Brasov Cty Emergency Hosp, Brasov, Romania
[7] Cty Hosp, Targu Mures, Romania
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 04期
关键词
LYMPHOCYTE STIMULATOR BLYS; HUMAN MONOCLONAL-ANTIBODY; COLLEGE-OF-RHEUMATOLOGY; AMERICAN-COLLEGE; B-CELLS; SUBJECT POPULATION; BELIMUMAB BMAB; DEFINITION; ANTAGONIST; ACTIVATION;
D O I
10.1002/art.37820
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Tabalumab, a fully human IgG4 monoclonal antibody, neutralizes soluble and membrane-bound BAFF. The aim of this study was to examine the tolerability and efficacy of tabalumab in patients with active rheumatoid arthritis receiving methotrexate. Methods In this randomized, double-blind, placebo-controlled, parallel, multiple-dose study, patients who were naive to biologic therapy received infusions of tabalumab (30, 60, or 160 mg) or placebo at weeks 0, 3, and 6 in combination with methotrexate and were evaluated for 24 weeks. The primary efficacy end point was the percentage of patients meeting American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 16. Results At week 16, the percentages of patients achieving an ACR20 response in the 30-mg (57.6%), 60-mg (67.6%), and 160-mg (51.5%) groups were significantly greater than the percentage of patients achieving an ACR20 response in the placebo group (29.4%; P < 0.05). There were initial transient increases from baseline in the frequency of CD20+ and IgD+/CD27 B cells, followed by reductions, although B cells were not completely depleted. Also, the frequency of IgD/CD27+ B cells increased in all tabalumab groups compared with the placebo group and returned toward baseline levels by the end of the study. The incidence of adverse events was similar across all treatment groups; no deaths occurred. Serum IgM levels decreased significantly in all tabalumab groups combined compared with the placebo group. There were no significant decreases in serum IgG or IgA levels in the tabalumab groups compared with the placebo group. Conclusion Tabalumab treatment significantly reduces the signs and symptoms of rheumatoid arthritis and has a safety profile similar to that seen with placebo treatment.
引用
收藏
页码:880 / 889
页数:10
相关论文
共 50 条
  • [11] COMBINATION THERAPY WITH METHOTREXATE AND CHLOROQUINE IN RHEUMATOID-ARTHRITIS - A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL
    FERRAZ, MB
    PINHEIRO, GRC
    HELFENSTEIN, M
    ALBUQUERQUE, E
    REZENDE, C
    ROIMICHER, L
    BRANDAO, L
    SILVA, SC
    PINHEIRO, GC
    ATRA, E
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1994, 23 (05) : 231 - 236
  • [12] Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
    Matsubara, Tsukasa
    Inoue, Hiroshi
    Nakajima, Toshihiro
    Tanimura, Kazuhide
    Sagawa, Akira
    Sato, Yukio
    Osano, Kei
    Nagano, Shuji
    Ueki, Yukitaka
    Hanyu, Tadamasa
    Hashizume, Koichi
    Amano, Norihito
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    RMD OPEN, 2018, 4 (02):
  • [13] Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
    Hara, Masako
    Ishiguro, Naoki
    Katayama, Kou
    Kondo, Masakazu
    Sumida, Takayuki
    Mimori, Tsuneyo
    Soen, Satoshi
    Nagai, Kota
    Yamaguchi, Tomonobu
    Yamamoto, Kazuhiko
    MODERN RHEUMATOLOGY, 2014, 24 (03) : 410 - 418
  • [14] Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
    Fleischmann, Roy
    Pangan, Aileen L.
    Song, In-Ho
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Ostor, AndrewJ
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (11) : 1788 - 1800
  • [15] A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
    Kingsley, Gabrielle H.
    Kowalczyk, Anna
    Taylor, Helen
    Ibrahim, Fowzia
    Packham, Jonathan C.
    McHugh, Neil J.
    Mulherin, Diarmuid M.
    Kitas, George D.
    Chakravarty, Kuntal
    Tom, Brian D. M.
    O'Keeffe, Aidan G.
    Maddison, Peter J.
    Scott, David L.
    RHEUMATOLOGY, 2012, 51 (08) : 1368 - 1377
  • [16] Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial.
    Burmester, Gerd R.
    Rigby, William
    van Vollenhoven, Ronald F.
    Kay, Jonathan
    Rubbert-Roth, Andrea
    Kelman, Ariella
    Dimonaco, Sophie
    Mitchell, Nina
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1182 - S1183
  • [17] Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
    Fiore, Stefano
    Genovese, Mark
    Fan, Chunpeng
    Decktor, Dennis
    Fleischmann, Roy
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1217 - 1217
  • [18] Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naive Patients With Rheumatoid Arthritis
    Emery, Paul
    Fleischmann, Roy M.
    Strusberg, Ingrid
    Durez, Patrick
    Nash, Peter
    Amante, Eric
    Churchill, Melvin A.
    Park, Won
    Pons-Estel, Bernardo
    Han, Chenglong
    Gathany, Timothy A.
    Zhou, Yiying
    Xu, Stephen
    Hsia, Elizabeth C.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S188 - S189
  • [19] FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Emery, Paul
    Fleischmann, Roy M.
    Strusberg, Ingrid
    Durez, Patrick
    Nash, Peter
    Amante, Eric
    Churchill, Melvin
    Park, W.
    Pons-Estel, Bernardo
    Han, Chenglong
    Gathany, Tim
    Zhou, Yiying
    Xu, Stephen
    Hsia, Elizabeth C.
    RHEUMATOLOGY, 2014, 53 : 93 - 93
  • [20] Efficacy and safety of abatacept in biologic-naive patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study
    Tanaka, Yoshiya
    Matsubara, Tsukasa
    Hashizume, Koichi
    Amano, Norihito
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2022, 32 (03) : 500 - 507